Postdoctoral scholar Dr. Dmytro Havrylyuk received an award for the poster “Ru(II) CYP1B1 Inhibitor Prodrugs with Enhanced Potency” at the 2018 Metals in Medicine, Gordon Research Conference. The project was performed in collaboration with Kimberly Stevens and Catherine A. Denning in the laboratories of Dr. David K. Heidary and Prof. Edith C. Glazer
Dr. Havrylyuk described the development of highly potent and selective inhibitors of Cytochrome P450 1B1 (CYP1B1), an enzyme that is involved in cancer initiation, progression, and resistance to treatment. CYP1B1 is overexpressed in a wide variety of human tumors, giving it the title of “universal tumor antigen”. The enzyme catalyzes the 4-hydroxylation of 17β-estradiol to form a 3,4-quinone, which reacts with DNA, inducing mutation. CYP1B1 is also implicated in cancer